The current standard in assessing eligibility for ICB treatment in NSCLC is levels of PD-L1 protein in the tumor, as commonly prescribed ICBs directly target PD-L1 or its receptor PD-1. The gene discussed is CD274; the disease is non-small cell lung carcinoma.